Wir haben keinen Außendienst, daher versenden wir gern kostenlose Produktproben und Informationen an medizinisches Fachpersonal. Durch unseren Musterversand möchten wir Ihnen die Möglichkeit geben, sich selbst ein Bild zu machen, Ihre Patienten umfassend und einfach zu beraten und ihnen eine evidenzbasierte Option anzubieten.
The symposium highlights current scientific and clinical aspects of the vitreous: from new treatment options for vitreous opacities aimed at improving quality of life, to the impact on the efficacy of intravitreal medication, modern replacement techniques, and the latest scientific insights into the role of hyalocytes. The goal is to deepen the understanding of the vitreous, provide insight into current research and preclinical work, and offer new impulses for diagnostics and therapy in direct patient care.
ebiga-Vision is a company specializing in vision science, committed to diagnosing, preventing, and treating eye conditions and chronic diseases affecting vision. Headquartered in Greifswald, the family-owned business aims to equip ophthalmologists and patients, both in Germany and internationally, with cutting-edge tools to help prevent chronic eye disorders. With a focus on research and development, ebiga-Vision also offers nutritional supplements designed to meet the specific micronutrient needs of the eyes. Their current areas of focus include vitreous degeneration, diabetes-related eye issues, macular degeneration, and glaucoma.
We do not have a field service, so we are pleased to send you free product samples and information. Through our sample distribution, we want to give you the opportunity to form your own opinion, provide your patients with comprehensive and straightforward advice, and offer them an evidence-based option.
This year, we are once again represented at various ophthalmology congresses across the world.
Whether large professional trade fairs or specialized events, each offers a valuable opportunity to engage in dialogue with dedicated experts. We look forward to exchanging insights on our evidence-based products and the current state of clinical research, as well as to inspiring discussions on the potential of micronutrients for eye health.
Approximately 75% of people experience floaters, and 33% find them bothersome. According to a UK study, the average optometrist sees 14 patients per month complaining about floaters. With such a high prevalence and a significant proportion of affected individuals reporting discomfort, should the conventional “watch and wait” approach be reconsidered?
During the 35th International Congress of the German Ophthalmic Surgery Society, ebiga-VISION invited renowned scientists and ophthalmologists to a satellite symposium dedicated to the vitreous body. The presentations and discussions by doctors and researchers summarized the latest findings on vitreous degeneration, its impact on visual performance and quality of life, as well as both surgical and non-surgical treatment options for everyday clinical practice.
Eye floaters can be more than just a minor nuisance – they often affect patients’ daily lives. However, discussing treatment options can be challenging. In an expert discussion, leading specialists shared their clinical experiences and approaches to treating vitreous opacities.
Four publications in recent years have demonstrated that after three to six months of supplementation with 150 mg of R-alpha-lipoic acid (contained in 300 mg of racemate), 1.1 mg of vitamin B1, 1.4 mg of vitamin B2, and 25 mg of rutin, both visual function and functional as well as morphological parameters of the retina improved significantly.
The vitreous body has a unique protective mechanism against oxidative stress and collagen glycation. However, this mechanism loses efficacy during degeneration. Providing the eye with naturally occurring micronutrients can help reactivate this mechanism, minimising or even preventing collagen fibres from clumping. Discover all about VitroCap®N, including its ingredients, mechanism of action, clinical study data, and expert panel discussions with eye care professionals who have up to 10 years of experience using the product.
Since 2013, extensive scientific studies have investigated important new findings on the effectiveness of VitroCap®N. In five clinical studies, European researchers observed significant improvements in patients with vitreous opacities through the intake of the micronutrients contained in VitroCap®N.
A big thank you to Martin Oguzie from the YouTube channel “Martin the Optometrist” for this incredible, self-driven work. In his video, Martin takes a thoughtful deep dive into VitroCap®N…
Oxidative stress plays a key role in #glaucoma pathogenesis, contributing to mitochondrial dysfunction, DNA damage, and retinal ganglion cell apoptosis. Current research in this area focuses on the ???? Oxidative…
